Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.

ABSTRACT:

Background

Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an open-label phase IV trial.

Objective

To assess the clinical benefit with sunitinib using the combined data from these trials.

Patients and methods

An updated overall survival (OS) in patients with panNETs for the phase IV trial was provided, and an analysis of results from the sunitinib-treated combined cohort from the phase III and IV trials (combined cohort) was conducted to assess PFS, OS, and objective response rate (ORR).

Results

The updated median OS for the phase IV trial was 54.1 months (95% CI 37.9-not

SUBMITTER: Fazio N 

PROVIDER: S-EPMC7810649 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature